Floatz logo

Aldafermin

Primary Biliary Cirrhosis

NGM Biopharmaceuticals, Incprotein_peptidePhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Primary Biliary Cirrhosis cohort.

Asset / SponsorPhaseRating
URSODEOXYCHOLIC ACID
Xijing Hospital of Digestive Diseases
Phase 4A
Saroglitazar
Zydus Therapeutics Inc.
Phase 3BB
Fenofibrate
Xijing Hospital of Digestive Diseases
Phase 3BB
cs0159
Cascade Pharmaceuticals, Inc
Phase 3BB
Obeticholic Acid
Intercept Pharmaceuticals
Phase 3BB

View all 50 →

Same molecule, other indications

Aldafermin is also rated in:

metabolic dysfunction-associated steatohepatitisDormant
BB
Indicative ·
66 / 100
View asset →
primary sclerosing cholangitisDormant
B
Indicative ·
62 / 100
View asset →
cirrhosis of liverDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →